<DOC>
	<DOC>NCT01180751</DOC>
	<brief_summary>This clinical trial is being conducted to study the use of a radioactive glucose tracer as an imaging test [Positron Emission Tomography (PET)scan] in adults who have or are suspected of having cancer and in another group of adults to assess for neurologic conditions.</brief_summary>
	<brief_title>18F-Fluorodeoxyglucose Positron Emission Tomography in Oncology and Neurology</brief_title>
	<detailed_description />
	<mesh_term>Deoxyglucose</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>Known or suspected primary or metastatic tumours A neurological presentation consistent with the list of indications 18 years of age or older of either sex Able to provide written informed consent Able to tolerate the physical and logistical requirements of completing a Positron Emission Tomography (PET)scan Karnofsky score &gt; 60 Women who are nursing may be included in the study if they are able to discontinue breast feeding for 12 hours Age &lt;18 years Pregnant women; if there is a possibility of pregnancy, bloodwork will be drawn to definitively establish pregnancy status Women who are unwilling or unable to discontinue breast feeding for 12 hours post 18FFluorodeoxyglucose(FDG) administration Subjects who are medically unstable Subjects unwilling to provide informed consent. Subjects who exceed the safe weight limit of the Positron Emission Tomography (PET) imaging bed or who cannot fit through the PET scanner bore</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Positron Emission Tomography</keyword>
	<keyword>Fluorodeoxyglucose</keyword>
	<keyword>FDG (18F-Fluorodeoxyglucose)</keyword>
	<keyword>Oncology</keyword>
	<keyword>Neurology</keyword>
</DOC>